Metformin Use May Increase Risk of Pancreatic Cancer in Diabetic Women: An Analysis of the Korean National Health Insurance Service-National Health Screening Cohort Database
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: In addition to its antidiabetic effects, metformin has pleiotropic effects, such as the inhibition of carci-nogenesis. This study aimed to investigate the association between metformin use and pancreatic cancer risk in the Korean National Health Insurance Service (NHIS)-National Health Screening Cohort (HEALS).Methods: Of the individuals in the Korean NHIS-HEALS, 29,271 men and 19,091 women were included in the final analysis after propensity score matching based on age, body mass index, and smoking status. The study population was categorized into three groups: metformin non-users with diabetes mellitus (DM), metformin users with DM, and non-diabetic users. A Cox proportional hazards regression model was used to examine the association be-tween metformin use and pancreatic cancer.Results: The median follow-up period was 12.9 years. The estimated pancreatic cancer incidence was highest in metformin users with DM, regardless of sex (P<0.001), and lowest in non-diabetic men and female metformin non-users (P=0.053). The hazard ratios (95% confidence interval) for pancreatic cancer incidence in metformin users and non-diabetic individuals were 1.116 (0.648–1.923) and 0.447 (0.259–0.771) in men and 2.769 (1.003–7.642) and 1.451 (0.529–3.984) in women, respectively, after full adjustment.Conclusion: Women with diabetes using metformin are at a higher risk of pancreatic cancer than women with dia-betes not using metformin. Meanwhile, men with DM using metformin have a similar risk of pancreatic cancer as men with DM not using metformin.
Abstract
Background: In addition to its antidiabetic effects, metformin has pleiotropic effects, such as the inhibition of carci-nogenesis. This study aimed to investigate the association between metformin use and pancreatic cancer risk in the Korean National Health Insurance Service (NHIS)-National Health Screening Cohort (HEALS).Methods: Of the individuals in the Korean NHIS-HEALS, 29,271 men and 19,091 women were included in the final analysis after propensity score matching based on age, body mass index, and smoking status. The study population was categorized into three groups: metformin non-users with diabetes mellitus (DM), metformin users with DM, and non-diabetic users. A Cox proportional hazards regression model was used to examine the association be-tween metformin use and pancreatic cancer.Results: The median follow-up period was 12.9 years. The estimated pancreatic cancer incidence was highest in metformin users with DM, regardless of sex (P<0.001), and lowest in non-diabetic men and female metformin non-users (P=0.053). The hazard ratios (95% confidence interval) for pancreatic cancer incidence in metformin users and non-diabetic individuals were 1.116 (0.648–1.923) and 0.447 (0.259–0.771) in men and 2.769 (1.003–7.642) and 1.451 (0.529–3.984) in women, respectively, after full adjustment.Conclusion: Women with diabetes using metformin are at a higher risk of pancreatic cancer than women with dia-betes not using metformin. Meanwhile, men with DM using metformin have a similar risk of pancreatic cancer as men with DM not using metformin.
참고문헌 (27)
- American Diabetes Association, "9. Pharmacologic approaches to glycemic treatment : standards of medical care in diabetes-2019", Diabetes Care, 42(Suppl 1), pp.S90~S102 (2019)
- Davies MJ, "Management of hyperglycaemia in type 2 diabetes, 2018 : a consensus report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)", Diabetologia, 61, pp.2461~2498 (2018)
- Rena G, "The mechanisms of action of metformin", Diabetologia, 60, pp.1577~1585 (2017)
- UK Prospective Diabetes Study(UKPDS)Group, "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34)", Lancet, 352, pp.854~865 (1998)
- Madiraju AK, "Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase", Nature, 510, pp.542~546 (2014)
- McIntyre HD, "Metformin increases insulin sensitivity and basal glucose clearance in type 2(non-insulin dependent)diabetes mellitus", Aust N Z J Med, 21, pp.714~719 (1991)
- Viollet B, "Cellular and molecular mechanisms of metformin: an overview", Clin Sci (Lond), 122, pp.253~270 (2012)
- 전상민, "Regulation and function of AMPK in physiology and diseases", Experimental and Molecular Medicine, 48, pp.1~13 (2016), 생화학분자생물학회
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2021", Cancer Research and Treatment, 53(2), pp.316~322 (2021), 대한암학회[DOI]
- Annual report of cancer statistics in Korea in 2018, "Ministry of Health and Welfare", Ministry of Health and Welfare, ~ (2018)
- Tempero MA, "Pancreatic adenocarcinoma, version 2 : 2017, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 15, pp.1028~1061 (2017)
- Tseng CH, "Metformin and pancreatic cancer risk in patients with type 2 diabetes", Pancreas, 47, pp.e57~e59 (2018)
- Lee DY, "The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer : a nationwide population-based study in Korea", Sci Rep, 8, pp.9719~ (2018)
- Liao KF, "Diabetes mellitus correlates with increased risk of pancreatic cancer : a population-based cohort study in Taiwan", J Gastroenterol Hepatol, 27, pp.709~713 (2012)
- Kim YI, "Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment : a nationwide cohort study", Aliment Pharmacol Ther, 39, pp.854~863 (2014)
- Ruiter R, "Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives : results from a large population-based follow-up study", Diabetes Care, 35, pp.119~124 (2012)
- Wang Z, "Metformin is associated with reduced risk of pancreatic cancer in patients with type 2diabetes mellitus : a systematic review and meta-analysis", Diabetes Res Clin Pract, 106, pp.19~26 (2014)
- Wirunsawanya K, "Survival benefits from metformin use in pancreatic cancer : a systemic review and metaanalysis", Pancreas, 47, pp.e11~e14 (2018)
- Chen K, "Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer", Mol Cancer, 16, pp.131~ (2017)
- Ferrara A, "Cohort study of pioglitazone and cancer incidence in patients with diabetes", Diabetes Care, 34, pp.923~929 (2011)
- Lu Y, "New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer", Br J Cancer, 113, pp.1607~1614 (2015)
- Kisfalvi K, "Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth", Cancer Res, 69, pp.6539~6545 (2009)
- Rozengurt E, "Mechanistic target of rapamycin(mTOR) : a point of convergence in the action of insulin", IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells, 2014, pp.5, 357~
- Parr MK, "NDMA impurity in valsartan and other pharmaceutical products : analytical methods for the determination of N-nitrosamines", J Pharm Biomed Anal, 164, pp.536~549 (2019)
- "Statement from Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S" (2019)[URL]
- Tempero MA, "Pancreatic adenocarcinoma, version 2 : 2021, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 19, pp.439~457 (2021)
- Humphris JL, "Clinical and pathologic features of familial pancreatic cancer", Cancer, 120, pp.3669~3675 (2014)